bevacizumab   Click here for help

GtoPdb Ligand ID: 6771

Synonyms: Avastin® | rhuMAb-VEGF
Approved drug
bevacizumab is an approved drug (FDA (2004), EMA (2005))
Compound class: Antibody
Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.
NameTrade nameCompanyClinical PhaseIndications
bevacizumab-awwbMvasiAmgenApproved (FDA 2017)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535ZirabevPfizerApproved (EMA & FDA 2019)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8AybintioSamsung BioepisApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238EquidacentCentus BiotherapeuticsApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
CBT124 Cipla BioTechPhase 3
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2004), EMA (2005))
WHO Essential Medicine WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.
International Nonproprietary Names Click here for help
INN number INN
8017 bevacizumab
Synonyms Click here for help
Avastin® | rhuMAb-VEGF
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 24
Reactome Drug Reactome logo R-ALL-9679458
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 178103377
PubChem SID 178103377
Search PubMed clinical trials bevacizumab
Search PubMed titles bevacizumab
Search PubMed titles/abstracts bevacizumab
Wikipedia Bevacizumab